Unproven Lifeline? Nalmefene’s Missing Tests in the Synthetic Opioid Era

It seems we may have spoken too soon about the nalmefene hydrochloride auto-injector for opioid overdoses. It turns out no one really knows if there’s enough clinical data to support its use in the current landscape of high-potency synthetic opioids. That’s a pretty big oversight for a company releasing an opioid reversal agent. There are also concerns about severe and prolonged withdrawal due to its long half-life of 10.8 hours.

And, in a twist of irony, this drug is produced by the same company that devastated countless lives with OxyContin—Purdue Pharma. You have to hand it to them; they really have no shame. While I’m always eager for new tools to save lives, it’s shocking that they didn’t properly test the medication against the very synthetic opioids flooding the market. I guess we’ll soon find out if this new option will be helpful in emergency situations.